Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Yeung

Urology Gainesville, FL Medical Doctor

NPI 1104909548 CMS profile 140510

1600 Sw Archer Rd, Gainesville, FL 32610

Open in the dashboard

General payments

$67,685

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Yeung of Gainesville, FL is reported in the CMS Open Payments database as having received $67,685 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,314 28
2024 General $23,761 12
2023 General $1,155 7
2022 General $174 3
2021 General $3,131 3
2019 General $151 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Yeung
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Lawrence Yeung were reported at $39,314. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Lawrence Yeung Urology median Middle half National median
2019 $151 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $3,131 $358 $111–$1,000 $132
2022 $174 $476 $143–$1,263 $149
2023 $1,155 $560 $168–$1,461 $160
2024 $23,761 $563 $170–$1,464 $164
2025 $39,314 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Uromedica, Incorporated $51,939 19 payments
  2. Endo USA, Inc. $10,350 15 payments
  3. Intuitive Surgical, Inc. $3,117 3 payments
  4. Coloplast Corp $1,035 10 payments
  5. Endo Pharmaceuticals Inc. $420 1 payment
  6. Laborie Medical Technologies Corp. $308 2 payments
  7. Astellas Pharma US Inc $301 3 payments
  8. Innovation Technologies Inc $123 1 payment
  9. Boston Scientific Corporation $92 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $47,530 10 payments
  2. Travel and Lodging $9,474 14 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,000 2 payments
  4. Education $3,840 2 payments
  5. Food and Beverage $2,842 27 payments
Products named General payments · program years 2019–2025
  1. ProACT $51,939 19 payments
  2. XIAFLEX $9,930 14 payments
  3. Da Vinci Surgical System Surgery $3,000 1 payment
  4. Titan Men's Health $866 7 payments
  5. XTANDI $301 3 payments
  6. TITAN Penile Reconstruction $151 2 payments
  7. Optilume BPH Drug Coated Balloon Catheter $144 1 payment
  8. Irrisept $123 1 payment
  9. Da Vinci Surgical System Surgery $117 2 payments
  10. AMS 700 $92 1 payment
  11. Other $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

101

Median for Urology: 1,053

Drug cost

$1,042

Median for Urology: $101,464

Branded share of claims

12.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Testosterone Cypionate Generic 27 $487
Tamsulosin Hcl Generic 32 $314
Alfuzosin Hcl Er Alfuzosin Hcl Brand 13 $122
Ciprofloxacin Hcl Generic 29 $118

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$93,640

Of which drugs: $2,133

Medicare patients

385

Average age 72

Services billed

2,295

89 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Cancer 41%
Ischemic heart disease 39%
Chronic kidney disease 38%
Diabetes 36%
Atrial fibrillation 28%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 13 884 $2,052
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 11 22 $45

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record